- CA$57.46m
- CA$69.38m
- CA$0.43m
- 25
- 18
- 26
- 12
Annual income statement for MedMira, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2019 July 31st | 2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.527 | 0.919 | 2.14 | 0.952 | 0.433 |
Cost of Revenue | |||||
Gross Profit | 0.423 | 0.572 | 1.72 | 0.304 | 0.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 1.82 | 2.22 | 2.14 | 2.22 | 2.21 |
Operating Profit | -1.3 | -1.3 | 0.006 | -1.27 | -1.78 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -2.11 | -2.05 | -0.676 | -1.83 | -2.68 |
Net Income After Taxes | -2.11 | -2.05 | -0.676 | -1.83 | -2.68 |
Net Income Before Extraordinary Items | |||||
Net Income | -2.11 | -2.05 | -0.676 | -1.83 | -2.68 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -2.11 | -2.05 | -0.676 | -1.83 | -2.68 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.003 | -0.003 | -0.001 | -0.003 | -0.004 |